Report #2895234

Received May 4, 2026

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: 60 yrs
State: TN
Recovered: Unknown
Vaccinated: Apr 16, 2026
Onset: Apr 16, 2026
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
HEPAB	HEP A + HEP B (TWINRIX)	GLAXOSMITHKLINE BIOLOGICALS	2	2553X	—

Symptoms (1)

Inappropriate schedule of product administration

Symptom narrative

Late second dose; This non-serious case was reported by a other health professional via call center representative and described the occurrence of drug dose administration interval too long in a 60-year-old female patient who received HAB (Twinrix) (batch number 2553X) for prophylaxis. Previously administered products included Twinrix (received first dose on 30-SEP-2025). On 16-APR-2026, the patient received the 2nd dose of Twinrix. On 16-APR-2026, an unknown time after receiving Twinrix, the patient experienced drug dose administration interval too long (Verbatim: Late second dose). The outcome of the drug dose administration interval too long was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.